News

The Phase 1 portion of the seviteronel study has completed and a once-daily dose was selected for advancement into Phase 2 development. William Moore, Ph.D., Innocrin’s Chief Executive

Orphan drug designation provides certain exclusivity benefits, tax credits for certain research, longer exclusivity and a waiver of the New Drug Application user fee. The designation is made

An independent data monitoring committee observed that patients taking the drug in the trial were at a possible increased risk for death and other severe adverse events as

About 60,000 people in the US are diagnosed with DTC per year, and radioactive iodine (RAI) is recommended for those with known/suspected metastases at diagnosis and at high

Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital. All existing investors participated in the financing: Eshelman Ventures, Hatteras Venture

The compound is an oral and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1), which is being developed by H3 Biomedicine as an anticancer therapeutic

GR-MD-02 targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. The trial, which has enrolled 30 patients with advanced fibrosis, will last for

The new macromolecule features various specialized components that create a triple-play action to avoid drug resistance. A specialized component of the macromolecule allows better hydrogen bonds with electrostatic

The commission granted approval for Bristol-Myers Squibb’s (BMS) Opdivo in combination with Yervoy to treat advanced (unresectable or metastatic) melanoma in adults. In the first Phase 3, double-blind,